Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.

Alfredo Piccerillo; Maya El Hachem; May El Hachem; Rita De Vito; Erika Valentina De Luca; Ketty Peris

doi:10.1001/jamadermatol.2020.0304

Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.

Alfredo Piccerillo, Maya El Hachem, May El Hachem, Rita De Vito, Erika Valentina De Luca, Ketty Peris

IRCCS Ospedale pediatrico Bambino Gesù - Roma

Research output: Contribution to journal › Article

3 Citations (Scopus)

Abstract

Immunomodulating agents such as anti–programmed cell death protein 1 (PD-1) have recently gained a crucial role in the treatment of numerous human malignant tumors.1 Cemiplimab is a novel PD-1 blocker approved for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) in patients who are not candidates for curative surgery or radiation.2 During the last few years, other anti–PD-1 agents such as pembrolizumab and nivolumab have occasionally been used off-label to manage cases of advanced cSCC.3 We describe 1 patient with recessive dystrophic epidermolysis bullosa (RDEB) and multiple cSCCs who was successfully treated with pembrolizumab.

Original language	English
Pages (from-to)	N/A-N/A
Journal	JAMA Dermatology
Volume	2020
DOIs	https://doi.org/10.1001/jamadermatol.2020.0304
Publication status	Published - 2020

Keywords

Pembrolizumab
distrophyc epidermolisis bullosa
multiple SCC

Access to Document

10.1001/jamadermatol.2020.0304

Cite this

@article{8838d17cd750429897aee4596e719f90,

title = "Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.",

abstract = "Immunomodulating agents such as anti–programmed cell death protein 1 (PD-1) have recently gained a crucial role in the treatment of numerous human malignant tumors.1 Cemiplimab is a novel PD-1 blocker approved for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) in patients who are not candidates for curative surgery or radiation.2 During the last few years, other anti–PD-1 agents such as pembrolizumab and nivolumab have occasionally been used off-label to manage cases of advanced cSCC.3 We describe 1 patient with recessive dystrophic epidermolysis bullosa (RDEB) and multiple cSCCs who was successfully treated with pembrolizumab.",

keywords = "Pembrolizumab, distrophyc epidermolisis bullosa, multiple SCC, Pembrolizumab, distrophyc epidermolisis bullosa, multiple SCC",

author = "Alfredo Piccerillo and {El Hachem}, Maya and {El Hachem}, May and {De Vito}, Rita and {De Luca}, {Erika Valentina} and Ketty Peris",

year = "2020",

doi = "10.1001/jamadermatol.2020.0304",

language = "English",

volume = "2020",

pages = "N/A--N/A",

journal = "JAMA Dermatology",

issn = "2168-6068",

publisher = "American Medical Association",

}

TY - JOUR

T1 - Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.

AU - Piccerillo, Alfredo

AU - El Hachem, Maya

AU - El Hachem, May

AU - De Vito, Rita

AU - De Luca, Erika Valentina

AU - Peris, Ketty

PY - 2020

Y1 - 2020

N2 - Immunomodulating agents such as anti–programmed cell death protein 1 (PD-1) have recently gained a crucial role in the treatment of numerous human malignant tumors.1 Cemiplimab is a novel PD-1 blocker approved for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) in patients who are not candidates for curative surgery or radiation.2 During the last few years, other anti–PD-1 agents such as pembrolizumab and nivolumab have occasionally been used off-label to manage cases of advanced cSCC.3 We describe 1 patient with recessive dystrophic epidermolysis bullosa (RDEB) and multiple cSCCs who was successfully treated with pembrolizumab.

AB - Immunomodulating agents such as anti–programmed cell death protein 1 (PD-1) have recently gained a crucial role in the treatment of numerous human malignant tumors.1 Cemiplimab is a novel PD-1 blocker approved for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) in patients who are not candidates for curative surgery or radiation.2 During the last few years, other anti–PD-1 agents such as pembrolizumab and nivolumab have occasionally been used off-label to manage cases of advanced cSCC.3 We describe 1 patient with recessive dystrophic epidermolysis bullosa (RDEB) and multiple cSCCs who was successfully treated with pembrolizumab.

KW - Pembrolizumab

KW - distrophyc epidermolisis bullosa

KW - multiple SCC

KW - Pembrolizumab

KW - distrophyc epidermolisis bullosa

KW - multiple SCC

UR - http://hdl.handle.net/10807/152564

U2 - 10.1001/jamadermatol.2020.0304

DO - 10.1001/jamadermatol.2020.0304

M3 - Article

SN - 2168-6068

VL - 2020

SP - N/A-N/A

JO - JAMA Dermatology

JF - JAMA Dermatology

ER -

Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this